Historically, treatment options available for cancer included surgery, chemotherapy, radiation, and targeted therapy. Immuno-Oncology—also referred to as I-O therapy
or cancer immunotherapy—is showing great promise in the cancer field as a way to treat certain cancers. With “Immuno” as a reference to the immune system, Immuno-
Oncology uses drugs known as immunotherapies that target a body’s immune system to help fight cancer.
Although Immuno-Oncology therapies have been around for 30 years, significant advancements have occurred in the last year. The FDA has approved new I-O therapies—two in melanoma and one lung cancer—and they are now available to patients. At least 4 more approvals are expected in the coming year and the more than 900 I-O clinical trials active today will most likely result in additional FDA approvals.